fludarabine has been researched along with Encephalopathy, Toxic in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clement, NF; Dietrich, J; Hochberg, EP; Martinez-Lage, M; Winter, SF | 1 |
| Amado, R; Binder, G; Jakobsen, BK; Lowe, KL; Mackall, CL; Norry, E | 1 |
| Morgensztern, D; Peddi, PF; Peddi, S; Santos, ES | 1 |
| Brace, JR; Lee, MS; McKinney, AM; Santacruz, K | 1 |
| Bolgert, F; Camporo, P; Gonzalez, H; Leblond, V | 1 |
1 review(s) available for fludarabine and Encephalopathy, Toxic
| Article | Year |
|---|---|
Central nervous system toxicities of chemotherapeutic agents.
Topics: Antineoplastic Agents; Central Nervous System Diseases; Cisplatin; Cytarabine; Fluorouracil; Humans; Ifosfamide; Methotrexate; Neurotoxicity Syndromes; Posterior Leukoencephalopathy Syndrome; Vidarabine; Vincristine | 2014 |
4 other study(ies) available for fludarabine and Encephalopathy, Toxic
| Article | Year |
|---|---|
Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: An unexpected case of fludarabine-associated progressive leukoencephalopathy.
Topics: Aged; Antineoplastic Agents; Fatal Outcome; Humans; Immunotherapy, Adoptive; Leukoencephalopathies; Lymphoma, Large B-Cell, Diffuse; Male; Neurotoxicity Syndromes; Retroperitoneal Neoplasms; Vidarabine | 2021 |
Fludarabine and neurotoxicity in engineered T-cell therapy.
Topics: Antigens, CD19; Humans; Immunotherapy, Adoptive; Neurotoxicity Syndromes; Receptors, Antigen, T-Cell; T-Lymphocytes; Vidarabine | 2018 |
Clinical and imaging features of fludarabine neurotoxicity.
Topics: Adult; Antineoplastic Agents; Brain; Dose-Response Relationship, Drug; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurotoxicity Syndromes; Vidarabine | 2010 |
Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP).
Topics: Antineoplastic Agents; Demyelinating Diseases; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Neurotoxicity Syndromes; Vidarabine | 1999 |